| Sep 11 |
ARS Pharmaceuticals (SPRY): A Bull Case Theory
|
| Sep 10 |
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
|
| Sep 9 |
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
|
| Sep 7 |
Insider Returns Down To US$660k As ARS Pharmaceuticals' Stock Dips 12%
|
| Sep 6 |
ARS Pharmaceuticals, Inc. Upgraded to Buy: Here's Why
|
| Sep 6 |
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why
|
| Sep 6 |
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
|
| Sep 4 |
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
|
| Aug 26 |
ARS Pharma wins EU approval of epinephrine nasal spray
|
| Aug 26 |
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
|
